GM1 and GM2-Gangliosidosis: Clinical Features, Neuroimaging Findings and electroencephalography
Iranian Journal of Child Neurology,
Vol. 18 No. 2 (2024),
12 March 2024
,
Page 127-140
Abstract
Objectives
Gangliosidosis is one of the hereditary metabolic diseases caused by the accumulation of Gangliosid in the central nervous system, leading to severe and progressive neurological deficits. Regarding phenotype, GM1 and GM2-Gangliosidosis are divided into Infantile, Juvenile, and Adult.
Materials & Methods
In this study, thirty-seven patients with GM1 and GM2-Gangliosidosis were referred to the neurology department of Mofid Children’s Hospital in Tehran, Iran, whose disease was confirmed from September 2019 bto December 2021. This study assessed age, sex, and developmental status before the onset of the disease, clinical manifestations, brain imaging, and electroencephalography.
Results
97.20% of patients were the result of family marriage. Approximately 80% of juvenile patients were developmentally normal before the onset of the disease. Developmental delay was more common among infantile GM1-Gangliosidosis than infantile GM2-Gangliosidosis, but in total, more than 50% of GM1&GM2-Gangliosidosis patients had reached their developmental milestone before the onset of the disease. With the onset of disease symptoms, 100% of patients regressed in terms of movement, 97.20% of them mentally, and 75% of them had seizures during the disease. The most common clinical findings were cherry-red spot, Mongolian spot, macrocephaly, organomegaly, hyperacusis, and scoliosis. The most common brain imaging findings included bilateral thalamus involvement, brain atrophy, PVL, and delayed myelination. The most common finding in electroencephalography was background low voltage with abnormal sharp waves.
Conclusion
This study concluded that most of the patients are the result of family marriage, and most of the juvenile patients are developmentally normal before the onset of the disease. In addition, more than 50% of infantile patients reach their developmental milestones before the onset of the disease. The most common clinical findings of these patients are seizures, cherry-red spot, macrocephaly, hyperacusis, Mongolian spot, and bilateral involvement of the thalamus.
- GM1 & GM2-Gangliosidosis; Developmental delay; Neurometabolic disorders; Genetic disorders
How to Cite
References
2. Jarnes Utz JR, Kim S, King K, Ziegler R, Schema L, Redtree ES, et al. Infantile gangliosidoses: Mapping a timeline of clinical changes. Molecular Genetics and Metabolism. 2017 Jun;121(2):170–9.
3. Regier DS, Proia RL, D’Azzo A, Tifft CJ. The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy. Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1(Suppl 1):663–73.
4. Maegawa GHB, Tropak M, Buttner J, Stockley T, Kok F, Clarke JTR, et al. Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem. 2007 Mar 23;282(12):9150–61.
5. Smith NJ, Winstone AM, Stellitano L, Cox TM, Verity CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol. 2012 Feb;54(2):176–82.
6. Kannebley JS, Silveira-Moriyama L, Bastos LOD, Steiner CE. Clinical Findings and Natural History in Ten Unrelated Families with Juvenile and Adult GM1 Gangliosidosis. JIMD Rep. 2015;24:115–22.
7. Neudorfer O, Kolodny EH. Late-onset Tay-Sachs disease. Isr Med Assoc J. 2004 Feb;6(2):107–11.
8. Scarpelli M, Tomelleri G, Bertolasi L, Salviati A. Natural history of motor neuron disease in adult onset GM2-gangliosidosis: A case report with 25 years of follow-up. Mol Genet Metab Rep. 2014;1:269–72.
9. Przybilla MJ, Ou L, Tăbăran AF, Jiang X, Sidhu R, Kell PJ, et al. Comprehensive behavioral and biochemical outcomes of novel murine models of GM1-gangliosidosis and Morquio syndrome type B. Mol Genet Metab. 2019 Feb;126(2):139–50.
10. Tsuji D, Akeboshi H, Matsuoka K, Yasuoka H, Miyasaki E, Kasahara Y, et al. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis. Ann Neurol. 2011 Apr;69(4):691–701.
11. Maegawa GHB, Banwell BL, Blaser S, Sorge G, Toplak M, Ackerley C, et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Molecular Genetics and Metabolism. 2009 Oct;98(1–2):215–24.
12. Jacobs JFM, Willemsen M a. a. P, Groot-Loonen JJ, Wevers RA, Hoogerbrugge PM. Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease. Bone Marrow Transplant. 2005 Nov;36(10):925–6.
13. Kyrkanides S, Miller JH, Brouxhon SM, Olschowka JA, Federoff HJ. beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Brain Res Mol Brain Res. 2005 Feb 18;133(2):286–98.
14. KARIMZADEH P, JAFARI N, NEJAD BIGLARI H, JABBEH DARI S, AHMAD ABADI F, ALAEE MR, et al. GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series). Iranian Journal of Child Neurology [Internet]. 2014 Apr 20 [cited 2022 Nov 16];8(3). Available from: https://doi.org/10.22037/ijcn.v8i3.5759
15. Bley AE, Giannikopoulos OA, Hayden D, Kubilus K, Tifft CJ, Eichler FS. Natural History of Infantile GM2 Gangliosidosis. Pediatrics. 2011 Nov 1;128(5):e1233–41.
16. Leal AF, Benincore-Flórez E, Solano-Galarza D, Garzón Jaramillo RG, Echeverri-Peña OY, Suarez DA, et al. GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies. IJMS. 2020 Aug 27;21(17):6213.
17. Pampiglione G, Harden A. Neurophysiological Investigations in GM 1 and GM 2 Gangliosidoses. Neuropediatrics. 1984 Sep;15(S 1):74–84.
- Abstract Viewed: 39 times